Resources

In collaboration with global stakeholders, the PATH Diagnostics program conceptualizes, develops, commercializes, and ensures access to quality-assured diagnostic technologies that guide clinical decision-making, support surveillance, and inform health policies in low- and middle-income countries (LMIC). We combine market access capabilities with broad technical expertise in developing and scaling up innovative solutions to the world’s most pressing health challenges.

PATH’s Diagnostics program facilitates the generation of actionable evidence to advance diagnostic solutions that are context appropriate, user-driven, and perform as required. Our evidence-generation capabilities are critical to rigorously evaluating products before advancing their development and ensuring that useful, high-quality, fit-for-purpose products enter the market.

India recorded more than 1.7 million new cases of HIV in the last 10 years between 2011 and 2021. To attain India's commitment to achieve the United Nations Programme on HIV/AIDS (UNAIDS) 95-95-95 targets by 2030 and end the AIDS epidemic as a public health threat by 2030 in line with Sustainable Development Goals, India needs to strengthen the prevention-testing-treatment-care continuum.Leveraging the experience of STAR phases 1 and 2, PATH has been implementing the STAR Phase 3 project in India. The implementation study was conducted to demonstrate the feasibility and acceptability of HIVST across specific populations. The study was conducted in 14 high HIV prevalence states of India through five service delivery models. A detailed analysis plan was developed to examine and review the findings from the study. As the study concluded in June 2022, the process of data analysis was conducted to understand the information collected from the study participants.PATH has developed high-quality, reliable, and ready-reference knowledge products like the summary report and a compendium of success stories on various interventions, lessons learnt and key takeaways of the HIV Self Testing project in India.

Indoor residual spraying (IRS) and insecticide-treated bed nets (ITNs) are cornerstone malaria prevention and control methods in Madagascar. From 2016 to 2020, non-pyrethroid IRS was deployed to complement standard pyrethroid ITNs in 14 districts with high malaria burden, targeting 5 to 9 districts each year. Districts received IRS for 1 to 3 consecutive years during the study period. This retrospective observational study uses routine data to evaluate the impacts of IRS overall, sustained IRS over multiple years, and achieving high (≥85%) IRS coverage (structures sprayed/found). We fit a multilevel mixed effects model to data from all 114 districts of Madagascar from July 2016 to June 2021. We estimated the effect of IRS exposure, consecutive years of IRS, and high IRS coverage on monthly population-adjusted RDT-confirmed malaria cases at health facility level. Facilities missing data, and communes missing geolocations were excluded, leaving 84% of records included. The model controlled for ITN survivorship, mass drug administration (MDA), precipitation, enhanced vegetation index (EVI), month, year, and district. Using the fitted model we predicted malaria cases under observed and no IRS scenarios and estimated the number of cases averted by IRS. IRS was associated with reduced case incidence and an estimated 196,075 (79,879-316,809) cases were averted in targeted districts (~15% of the 1.3m reported cases). The effect varied by district and was associated with ITN survivorship, MDA, precipitation, EVI, month and year. One year of IRS was associated with higher incidence versus two (IRR = 1.15, 95%CI = 1.03-1.29) or three (IRR = 1.16, 95%CI = 1.01-1.33). High coverage (achieved in 94% of IRS areas) was associated with a 12% lower incidence rate (IRR=0.88, CI=0.82-0.95) compared to areas with lower coverage. This study suggests that IRS together with ITNs may substantially reduce malaria incidence over ITNs alone, and high spray coverage and >1 year of IRS may confer additional benefits. This work highlights the value of routine data to evaluate the impact of intervention combinations and to inform future targeting decisions in Madagascar. (French)

PATH has been contributing to Myanmar’s healthcare transformation since 2012 and supports the government’s commitment to achieve universal health coverage by 2030. PATH provides technical support to implement innovative solutions, institutionalize sustainable engagement models, strengthen surveillance, track, and train healthcare workers, and collect and analyze data for these diseases.Myanmar has a high prevalence of infectious diseases, with rates of HIV and TB the second highest in Southeast Asia. To strengthen digital health and lab/diagnosis system, PATH is developing digital tools and innovative systems to enable more consistent HIV and TB prevention, testing, and treatment. This factsheet talks about various projects that PATH has implemented and is implementing towards tackling infectious diseases in Myanmar.